Literature DB >> 913023

Acebutolol disposition after intravenous administration.

P J Meffin, R A Winkle, F A Peters, D C Harrison.   

Abstract

The disposition of acebutolol has been studied following intravenous doses of 0.25 to 1.0 mg/kg in 9 healthy subjects using a specific chromatographic assay to determine concentrations of drug in blood. The mean blood clearance was 6.55 ml/min/kg and the mean renal clearance, 2.68 ml/min/kg. Blood clearance was found to have a coefficient of variation of 14% for the group, to be independent of dose, and to remain essentially constant over approximately 3 wk. The fraction of the dose excreted in the urine unchanged was 0.405. Data were fitted to an equation for a two-compartment model. The mean fast and slow half-lives were 6.08 and 156.8 min, respectively. The volume of the central compartment was 0.223 L/kg, and the volume of distribution at steady-state was 1.165 L/kg. The fraction of acebutolol unbound to plasma proteins was 0.743 and was independent of drug concentration in the range examined. Data obtained from 15-min infusions were used to predict plateau blood concentrations with good accuracy during an 8-hr dosage regimen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 913023     DOI: 10.1002/cpt1977225part1557

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Microdialysis sampling for determination of plasma protein binding of drugs.

Authors:  A M Herrera; D O Scott; C E Lunte
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

2.  Anxiolytic effects of acebutolol and atenolol in healthy volunteers with induced anxiety.

Authors:  S G Kilminster; M J Lewis; D M Jones
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology.

Authors:  Le Sun; Jin Sun; Zhonggui He
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

4.  Acebutolol in hypertension: relationships between drug concentration and effects.

Authors:  M A Martin; F C Phillips; G T Tucker; A J Smith
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

5.  Is there a relationship between the physical properties and cardioselectivity of beta-adrenoceptor antagonists?

Authors:  D B Jack
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

7.  Pharmacokinetics of acebutolol after intravenous bolus administration.

Authors:  A Roux; B Flouvat; N P Chau; B Letac; M Lucsko
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

Review 8.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

9.  Blood plasma binding of acebutolol and diacetolol in man.

Authors:  T J Coombs; C J Coulson; V J Smith
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

10.  Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.

Authors:  A Roux; A Le Liboux; B Delhotal; J Gaillot; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.